 Connection
Jordan Karlitz to Aged
This is a "connection" page, showing publications Jordan Karlitz has written about Aged.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.328 |
|
|
|
-
Greene M, Stieber B, Ozbay AB, Anderson J, LeMaster J, Dore M, Stukalin I, Arroyo J, Ebner DW, Fendrick AM, Karlitz JJ. Multitarget Stool DNA Versus Fecal Immunochemical Testing: A National Assessment of Follow-Up Colonoscopy by Race and Ethnicity. J Natl Compr Canc Netw. 2026 Jul; 24(7).
Score: 0.059
-
Greene M, Stieber B, LeMaster JW, Idriss R, Stukalin I, Zapatier J, Arroyo J, Anderson J, Karlitz JJ. Closing the loop in colorectal cancer screening: real-world adherence to follow-up colonoscopy after positive mt-sDNA vs FIT/FOBT, stratified by payer type. Curr Med Res Opin. 2025 Sep; 41(9):1629-1639.
Score: 0.056
-
Greene M, Gohil S, Stieber B, Ozbay AB, Le QA, Kakuturu R, LeMaster JW, Dore M, Fendrick AM, Anderson JC, Karlitz JJ. Utilization of colorectal cancer screening modalities in the United States (2017-2023): a national multi-payer claims database analysis. Curr Med Res Opin. 2025 Sep; 41(9):1619-1628.
Score: 0.056
-
Gohil S, Omar M, Carnes ML, Karlitz JJ, Usry N, Idriss R, Greene M. Adherence to multi-target stool DNA colorectal cancer screening among Medicare patients in Alabama. Curr Med Res Opin. 2026 May; 42(5):941-951.
Score: 0.015
-
Greene M, Camardo M, Karlitz JJ, Nowd P, Wang W, Anderson J, Kisiel J, Ebner D. Real-world adherence to multi-target stool DNA testing and its association with time to follow-up colonoscopy: a health-system analysis from Massachusetts General Hospital. Curr Med Res Opin. 2026 Feb; 42(2):205-219.
Score: 0.014
-
Greene M, Camardo M, Karlitz JJ, Nowd P, Son J, Fuerstein J, Li J, Rittner S. Adherence to multi-target stool DNA test and time to follow-up colonoscopy: real-world analysis of patients from the Beth Israel Lahey Health. Curr Med Res Opin. 2025 Oct; 41(10):1811-1823.
Score: 0.014
-
Greene M, Anderson J, LeMaster J, Arroyo J, Zapatier J, Bingham J, Kakuturu R, Karlitz JJ, Le Q. Real-World Adherence to Repeat Colorectal Cancer Screening With the Multi-Target Stool DNA Test in a Large, Insured, and Average-Risk Population. Cancer Med. 2025 Nov; 14(21):e71314.
Score: 0.014
-
Greene M, Le QA, Ozbay AB, Karlitz JJ, Fendrick AM. Completing the colorectal cancer screening process: impact of eliminating cost-sharing for follow-up colonoscopy. Curr Med Res Opin. 2025 Sep; 41(9):1697-1703.
Score: 0.014
-
Gohil S, D'Attilio D, Paladiya R, Ganguly A, Vergara CM, Karlitz JJ, Greene M. Adherence to multi-target stool DNA colorectal cancer screening and clinical follow-up in the Hartford HealthCare system. Int J Colorectal Dis. 2025 Sep 16; 40(1):200.
Score: 0.014
-
Greene M, Pew T, Sakthisivabalan L, Zapatier J, Arroyo J, López JVR, Karlitz JJ, Duarte M. Adherence to colorectal cancer screening with multi-target stool DNA testing among first-time average-risk users in federally qualified health centers. Curr Med Res Opin. 2025 Jun; 41(6):983-993.
Score: 0.014
-
Greene M, Pew T, Ozbay AB, Rincón López JV, Brooks D, Karlitz J, Duarte M. Impact of Spanish Language Outreach on Multi-Target Stool DNA Test Adherence in a Federally Qualified Health Center in the United States. Cancer Control. 2025 Jan-Dec; 32:10732748251343334.
Score: 0.014
-
Fendrick AM, Fisher DA, Saoud L, Ozbay AB, Karlitz JJ, Limburg PJ. Impact of Patient Adherence to Stool-Based Colorectal Cancer Screening and Colonoscopy Following a Positive Test on Clinical Outcomes. Cancer Prev Res (Phila). 2021 09; 14(9):845-850.
Score: 0.010
-
Fisher DA, Karlitz JJ, Jeyakumar S, Smith N, Limburg P, Lieberman D, Fendrick AM. Real-world cost-effectiveness of stool-based colorectal cancer screening in a Medicare population. J Med Econ. 2021 Jan-Dec; 24(1):654-664.
Score: 0.010
-
Montminy EM, Karlitz JJ, Landreneau SW. Progress of colorectal cancer screening in United States: Past achievements and future challenges. Prev Med. 2019 03; 120:78-84.
Score: 0.009
-
Charlton ME, Kahl AR, Greenbaum AA, Karlitz JJ, Lin C, Lynch CF, Chen VW. KRAS Testing, Tumor Location, and Survival in Patients With Stage IV Colorectal Cancer: SEER 2010-2013. J Natl Compr Canc Netw. 2017 12; 15(12):1484-1493.
Score: 0.008
-
Charlton ME, Karlitz JJ, Schlichting JA, Chen VW, Lynch CF. Factors Associated With Guideline-recommended KRAS Testing in Colorectal Cancer Patients: A Population-based Study. Am J Clin Oncol. 2017 Oct; 40(5):498-506.
Score: 0.008
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|